

Heck Reactions of 6- and 2-Halopurines

Tomáš Tobrman^[a] and Dalimil Dvořák*^[a]

Keywords: Nucleobases / Homogeneous catalysis / Nitrogen heterocycles / Heck reaction

Under the conditions of the Heck reaction, 9-benzyl-6-iodopurine affords mainly the corresponding 6,6'-dimer, the Heck product being formed only in low yield ($\leq 12\%$). With 7-benzyl-6-iodopurine the dimerization is suppressed and the Heck product is obtained in 32–91% yield. 9-Substituted 6-chloro-2-iodopurines react smoothly, giving 2-alkenyl-6-

chloropurines in 71–97% isolated yields. The reaction proceeds with alkenes bearing electron-withdrawing substituents (like CO_2Bu , COCH_3 , CN) and Ph, while vinyl acetate and dodec-1-ene are unreactive.

(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2008)

Introduction

Among a vast number of biologically active purine derivatives, alkenylpurines play an important role.^[1] 6-Alkenylpurines, for example, are associated with antimycobacterial,^[2] cytotoxic^[3] and cytokinin^[4] activity and with inhibition of 15-lipoxygenase.^[5] Some 6-alkenylpurines have been designed as covalent analogues of DNA base pairs^[6] or novel cross-linking agents,^[7] and have also been used for the synthesis of fluorescent nucleoside analogues.^[8] Moreover, 2-alkenyladenosine derivatives have been reported to function as inhibitors of adenosine receptors.^[9]

Several methodologies have been used for the preparation of alkenylpurines. 6-Styrylpurine was first prepared by condensation of 6-methylpurine with benzaldehyde in the presence of HCl.^[10] Another, more general, synthetic approach to 6-alkenylpurines, is based on Wittig reactions between 9-protected (purin-6-yl)methylene-triphenyl- λ^5 -phosphanes (Wittig reagents) and aldehydes or ketones.^[11] Cyclic 6-alkenylpurines have been prepared by intramolecular cyclization of 6-(hydroxyalkyn-1-yl)purines,^[12] while 6-enaminopurines are accessible by addition of amines to 6-alkynylpurines.^[13] Partial hydrogenation of 2-alkynyl^[14] and 8-alkynylpurines^[15] to give the corresponding alkenes has also been reported. Hydrogenation of 6-alkynylpurines to 6-alkenylpurines was reported to proceed satisfactorily only with 9-unprotected bases, with overhydrogenation taking place otherwise.^[4a] However, the most versatile methodology for the preparation of alkenylpurines – nowadays used almost without exception – is based on transition-metal-catalyzed cross-coupling reactions.^[16] Alkenylpurines


have thus been prepared by Pd-catalyzed reactions between halopurines or *O*-tosylpurines and alkenylstannanes,^[17] alkenylzinc,^[17c] or alkenylboron reagents.^[18] An opposite approach, involving coupling of 2-stannylated purines with alkenyl halides, has also been described.^[19] Heck reactions of 6-vinylpurines were reported to produce 6-alkenylpurines.^[4a]

From this point of view it is interesting that Heck reactions starting from halopurines have not yet been reported, with the exception of the reaction between 8-bromocaffeine and *tert*-butyl acrylate.^[20] Heck reactions of halopurines would be of key importance, since they would allow easy introduction of alkenes bearing EWG substituents such as CO_2R , CO , or CN , cases in which the corresponding alkenylstannanes and boronic acids are not commonly accessible. Recently, we have made attempts to perform Heck reactions on 6-halopurines, but without success. No reactions were observed under classical Heck conditions, whereas in the presence of Ti^{I} or Ag^{I} acetates the formation of N1-substituted hypoxanthine derivatives was observed.^[21] When the reactions were run in the presence of hydride donors such as triethylammonium formate, saturated products of “reductive Heck reactions” were obtained.^[22] Similarly, unsuccessful attempted vinylation of 6-halopurines with vinyl acetate under Heck conditions has been reported^[4a]

Recently, as part of our continuing efforts to accomplish Heck reactions of 6- and 2-halopurines, we observed the formation of 6,6'-purine dimer **2** as a main product, but together with a small amount of the desired Heck product **3**, in the reaction between iodopurine **1** and butyl acrylate in the presence of palladium catalyst without phosphane ligand (Scheme 1).^[23] Suppression of the dimerization could, thus, possibly open an avenue to Heck reactions of purine 6- and 2-halides. Purine dimers are highly polar compounds, and they could easily have evaded detection in previous research. Therefore, we reexamined the Heck reactions of 6- and 2-halopurines from this point of view.

[a] Department of Organic Chemistry, Institute of Chemical Technology, Prague
Technická 5, 2166 28 Prague 6, Czech Republic
Fax: +420-224-354-288
E-mail: Tomas.Tobrman@vscht.cz
dvorakd@vscht.cz

Supporting information for this article is available on the WWW under <http://www.eurjoc.org> or from the author.




Scheme 1. Reaction between 9-benzyl-6-iodopurine and butyl acrylate under the conditions of the Heck reaction.

Results and Discussion

Repetition of the reaction between 9-benzyl-6-iodopurine (**1**) and butyl acrylate under the previously described conditions^[21] confirmed that in the presence of Pd(PPh₃)₂-Cl₂ or Pd(PPh₃)₄ only decomposition of starting compounds takes place. However, when the reaction was performed under phosphane-free conditions the dimer **2** became the main product of the reaction, but accompanied by a small amount of the desired Heck reaction product **3** (Scheme 1). The reaction between **1** and butyl acrylate (4 equiv.) was then repeated in the presence of various bases (Et₃N, K₂CO₃, *i*Pr₂NEt, Ag₂CO₃) and solvents (NMP, DMF, CH₃CN) at different temperatures and with Pd(dba)₂ or Pd(OAc)₂ as a source of palladium, with the aim of maximizing the formation of the Heck product. It appeared that the reaction requires polar solvent and a temperature above 100 °C, which excludes solvents such as THF, acetonitrile, or toluene. The best results were obtained in DMF at 120 °C; however, the yields of the Heck product **3** did not exceed 12%. The use of a large excess of

butyl acrylate (56 equiv.) increased the yield only slightly, to 24%. The same result was obtained when the reaction was performed in an excess of butyl acrylate serving at the same time as solvent.

We next turned our attention to 7-benzyl-6-iodopurine (**4**), in the expectation that the formation of the corresponding 6,6'-dimer might be suppressed for steric reasons. Additionally, the reported lower reactivities of 6-halo-7-benzylpurines relative to their 9-benzyl analogues^[17c] might be disadvantageous for the dimer formation. To our delight, the desired Heck product **5a** was obtained in 53% yield when the reaction was catalyzed by Pd(OAc)₂ in the presence of *i*Pr₂NEt in DMF at 120 °C without phosphane ligand (Scheme 2, Table 1, Entry 1). To improve the yield, the reaction was further optimized. Similar result was obtained when Pd(dba)₂ was used instead of Pd(OAc)₂ (Table 1, Entry 2). In contrast, replacement of *i*Pr₂NEt with K₂CO₃ or the use of PdCl₂(PPh₃)₂ as catalyst suppressed the reaction (Table 1, Entries 3 and 4). The yield increased to 77%, however, in the presence of 1.1 equiv. of Ti₂SO₄ (Table 1, Entry 5), while application of Na₃PO₄ as a base led to further improvement and the reaction under phosphane-free conditions gave **5a** in 89% yield. The combination of Na₃PO₄ with diPheCy₂P lowered the yield to 50% (Table 1, Entries 6 and 7), but a high yield of the Heck product was obtained when Pd(OAc)₂ was used in combination with biPheCy₂P and *i*Pr₂NEt (Table 1, Entry 8). Since in this case the conversion of **4** was quantitative, which simplified separation of the product, these conditions were used for Heck reactions between **4** and other substrates. Under the above conditions, acrylonitrile, methyl vinyl ketone, and styrene



Scheme 2. Heck reactions of 7-benzyl-6-iodopurine.

Table 1. Heck reactions of 7-benzyl-6-iodopurine (**4**, Scheme 2).^[a]


Entry	R	Catalyst	Ligand	Base	% Yield ^[b]
1	CO ₂ Bu (5a)	Pd(OAc) ₂	none	<i>i</i> Pr ₂ NEt	53 ^[c]
2	CO ₂ Bu (5a)	Pd(dba) ₂	none	<i>i</i> Pr ₂ NEt	51
3	CO ₂ Bu (5a)	Pd(OAc) ₂	none	K ₂ CO ₃	trace
4	CO ₂ Bu (5a)	PdCl ₂ (PPh ₃) ₂	none	<i>i</i> Pr ₂ NEt	none
5	CO ₂ Bu (5a)	Pd(OAc) ₂	none	<i>i</i> Pr ₂ NEt	77 ^[d]
6	CO ₂ Bu (5a)	Pd(OAc) ₂	none	Na ₃ PO ₄	89 ^[c]
7	CO ₂ Bu (5a)	Pd(OAc) ₂	diPheCy ₂ P	Na ₃ PO ₄	50 ^[e]
8	CO ₂ Bu (5a)	Pd(OAc) ₂	diPheCy ₂ P	<i>i</i> Pr ₂ NEt	86 (53 ^[e])
9	CN (5b)	Pd(OAc) ₂	diPheCy ₂ P	<i>i</i> Pr ₂ NEt	49 ^[e]
10	CH ₃ CO (5c)	Pd(OAc) ₂	diPheCy ₂ P	<i>i</i> Pr ₂ NEt	32 ^[e]
11	Ph (5d)	Pd(OAc) ₂	diPheCy ₂ P	<i>i</i> Pr ₂ NEt	47 ^[e]

[a] Reaction conditions: a mixture of **4** with alkene (4 equiv.), base (2 equiv.), catalyst (5 mol-%), and DiPheCy₂P (10 mol-%) in dry DMF (5 mL per mmol of **4**) was stirred under argon for 18 h at 120 °C. [b] The yields were established by ¹H NMR with 2,3,5-trinitrobenzene as internal standard. [c] Unreacted iodopurine **4** was present in the reaction mixture. [d] 1.1 Equiv. of Ti₂SO₄ was used as additive. [e] Isolated yield.

afforded the expected Heck-type products in fair yields (Table 1, Entries 9–11). In each case the (*E*) isomer of the product was obtained exclusively. Vinyl acetate, as an example of an electron-rich alkene, gave only a dehalogenation product – 7-benzylpurine. 6-Chloro-7-benzylpurine did not react under these conditions at all.

We also examined the Heck reactions of 6-chloro-2-iodo derivatives **6a** and **6b** (Scheme 3). Since the chlorine in the 6-position is not reactive, such reactions should selectively lead to the 2-alkenyl-6-chloro derivatives. In this case there is a possibility of further derivatization of such compounds at the 6-position giving biologically relevant compounds. The results are summarized in Table 2. As expected, the products were obtained with exclusive 2-selectivity, the reaction proceeding more easily than with 6-iododerivatives, and the dimerization did not occur. The reaction of **6a** was optimized with the respect to the source of palladium, the base used, the ligand, and the solvent. In DMF the yields obtained span the range from 51 to 88%; again, phosphane-free conditions and *i*Pr₂NEt gave the best results (Entries 4, 8, 12, 13). Unlike the reactions with **1** and **4**, this reaction proceeds even in acetonitrile at 60 °C, giving the desired Heck product in 90% isolated yield after 3 h (Entry 15). Other less polar solvents such as THF, EtOAc, DCE, and toluene were less effective at this temperature, and only low levels of conversion of **6a** (2–9%) after prolonged reaction times were observed. To achieve acceptable reaction times with all substrates, acetonitrile as a solvent at 80 °C and Pd(dba)₂/*i*Pr₂NEt were used for the reactions of **6a** and **6b** with other alkenes. Under these conditions, the reactions of both substrates with acrylonitrile, butyl acrylate, ethyl vinyl

ketone, and styrene proceeded with high yields (Entries 18–23), but electron-rich substrates – vinyl acetate and dodec-1-ene – were unreactive. Only traces (≤3%) of the corresponding 2,2'-dimers were detected in the crude reaction mixtures under ligand-free conditions or when TFP or *o*-tolyl₃P were used as ligands. When the reactions were catalyzed with Pd(dba)₂/BipheCy₂P, formation of the 2,2'-dimer was not observed.



Scheme 3. Heck reactions of 6-chloro-2-iodopurine derivatives.

The sterically more demanding methyl methacrylate gave low conversion and a substantial amount of the dimer in the reaction with **6a** at 80 °C in acetonitrile. A higher reaction temperature was required in this case. However, even 3 d heating at 120 °C in DMF led only to 54% yield of the desired product **7h** (Table 2, Entry 23).

Table 2. Heck reactions of 2-iodopurines **6a** and **6b** (Scheme 3).^[a]

Entry	R, R ¹ , R ²	Catalyst	Base	Solvent, temperature [°C]	% Yield ^[b]
1	<i>i</i> Pr, H, CO ₂ Bu	Pd(OAc) ₂	Na ₃ PO ₄	DMF, 120	72
2	<i>i</i> Pr, H, CO ₂ Bu	Pd(OAc) ₂	K ₂ CO ₃	DMF, 120	51
3	<i>i</i> Pr, H, CO ₂ Bu	Pd(OAc) ₂	Et ₃ N	DMF, 120	73
4	<i>i</i> Pr, H, CO ₂ Bu	Pd(OAc) ₂	<i>i</i> Pr ₂ NEt	DMF, 120	79
5	<i>i</i> Pr, H, CO ₂ Bu	Pd(PPh ₃) ₄	<i>i</i> Pr ₂ NEt	DMF, 120	74
6	<i>i</i> Pr, H, CO ₂ Bu	PdCl ₂ (PPh ₃) ₂	<i>i</i> Pr ₂ NEt	DMF, 120	78
7	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	DMF, 120	84
8	<i>i</i> Pr, H, CO ₂ Bu	(C ₃ H ₅ PdCl) ₂	<i>i</i> Pr ₂ NEt	DMF, 120	79
9	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂ /TFP	<i>i</i> Pr ₂ NEt	DMF, 120	54
10	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂ / <i>o</i> -tolyl ₃ P	<i>i</i> Pr ₂ NEt	DMF, 120	73
11	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂ /BipheCy ₂ P	<i>i</i> Pr ₂ NEt	DMF, 120	60
12	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	DMF, 100	88
13	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	DMF, 80	85
14	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	85
15	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 60	90
16	<i>i</i> Pr, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 40	40 ^[c]
17	<i>i</i> Pr, H, Ph	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	87
18	<i>i</i> Pr, H, CH ₃ CO	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	97
19	<i>i</i> Pr, H, CN	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	80
20	AcRf, H, CO ₂ Bu	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	71
21	AcRf, H, Ph	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	78
22	AcRf, H, CH ₃ CO	Pd(dba) ₂	<i>i</i> Pr ₂ NEt	MeCN, 80	82
23	<i>i</i> Pr, CH ₃ , CO ₂ Bu	Pd(dba) ₂ /BipheCy ₂ P	<i>i</i> Pr ₂ NEt	DMF, 120 ^[d]	54

[a] Reaction conditions: a mixture of **6a** or **6b** with alkene (4 equiv.), base (2 equiv.), and catalyst (5 mol-%) in the indicated solvent (5 mL per mmol of **6**) was stirred under argon under the indicated conditions for three hours. [b] Isolated yield. [c] Unreacted **6a** remains in the reaction mixture. [d] Reaction time was 3 d.

Conclusions

The Heck reactions of 9-substituted 6-iodopurines are complicated by competitive dimerization, the Heck products being formed only in low yields. When 7-substituted 6-iodopurine derivatives are used, however, the dimerization is suppressed and the products of the Heck reaction can be isolated in about 30–50% yields.^[24] In contrast, the Heck reactions of 9-substituted 6-chloro-2-iodopurines proceed selectively at the 2-position, and the corresponding Heck products are formed smoothly in high yields, accompanied by only trace amounts of 2,2'-dimers. In most cases a catalytic system without phosphane ligand using Pd(dba)₂ [or a combination of Pd(dba)₂ with biPheCy₂P] and *i*Pr₂NEt as a base gave the best results.^[25]

Experimental Section

General: All reactions were performed under nitrogen. NMR spectra were measured on a Varian Gemini 300 (¹H, 300.07 MHz; ¹³C, 75.46 MHz), a Bruker AMX3 400 (¹H, 400.13 MHz and ¹³C, 100.62 MHz) or a Bruker DRX 500 Avance (¹H, 500.13 MHz and ¹³C, 125.77 MHz) spectrometer at 298 K. Unambiguous assignment of the NMR signals is based on ¹³C{¹H}, ¹³C APT, COSY, HMQC and ¹³C HMBC spectra. IR spectra were recorded on a Nicolet 750 FT-IR instrument. Mass spectra were measured on a ZAB-SEQ (VG Analytical) machine. The solvents were dried and degassed by standard procedures; silica gel (ICN Sil iTech, 32–63) was used for column chromatography. 9-Benzyl-6-iodopurine^[26] (**1**), 7-benzyl-6-iodopurine^[17c] (**4**), 9-benzyl-6-chloropurine,^[3] 6-chloro-2-iodo-9-isopropylpurine^[27] (**6a**), and 6-chloro-2-iodo-9-(*O,O*-triacetyl-β-D-ribofuranosyl)purine^[28] (**6b**) were prepared by the reported procedures; other compounds were purchased.

Butyl 3-(9-Benzylpurine-6-yl)acrylate (3): Dry DMF (0.5 mL), then butyl acrylate (2 mL, 14 mmol) and *i*Pr₂NEt (65 mg, 0.5 mmol) were added under argon to a mixture of 9-benzyl-6-iodopurine (**1**, 84 mg, 0.25 mmol) and Pd(dba)₂ (7 mg, 0.0125 mmol). The resulting mixture was then stirred at 120 °C for 18 h, silica (5 g) was added, volatiles were evaporated, and flash chromatography with EtOAc/hexane (2:1) afforded **3** (20 mg, 24%) as a colorless solid; m.p. 59–62 °C. ¹H NMR (CDCl₃): δ = 0.95 (t, *J* = 7.3 Hz, 3 H, CH₃), 1.42 (m, 2 H, CH₂), 1.70 (m, 2 H, CH₂), 4.24 (t, *J* = 6.5 Hz, 2 H, O-CH₂), 5.46 (s, 2 H, CH₂), 7.33 (m, 5 H, ArH), 7.62 (d, *J* = 16.0 Hz, 1 H, =CH), 8.1 (s, 1 H, 8-H), 8.1 (d, *J* = 16.0 Hz, 1 H, =CH), 9.0 (s, 1 H, 2-H) ppm. ¹³C NMR (CDCl₃): δ = 13.7, 19.1, 30.6, 47.4, 64.8, 127.8, 128.7, 129.2, 132.0, 134.8, 138.0, 145.2, 151.1, 152.5, 152.6, 166.2 ppm. IR (CHCl₃): ν̄ = 2962, 1713, 1583, 1496, 1454, 1403, 1326, 1299, 1278 cm⁻¹. HR MS (EI): calculated for C₁₉H₂₀N₄O₂: 336.1586; found 336.1561.

The corresponding-6,6'-dimer **2** is not eluted under these conditions and was not isolated. The presence of **6** in large amounts in the crude reaction mixture could, however, be shown by ¹H NMR [(CDCl₃, 300 MHz): δ = 5.54 (s, 4 H, CH₂Ph), 7.36 (br. s, 10 H, ArH), 8.23 (s, 2 H, H-8), 9.31 (s, 2 H, H-2) ppm].^[23]

General Procedure for Heck Reactions of 7-Benzyl-6-iodopurine (4): Dry DMF (3 mL), then the alkene (1 mmol) and *i*Pr₂NEt (65 mg, 0.5 mmol) were added under argon to a mixture of 7-benzyl-6-iodopurine (**4**, 84 mg, 0.25 mmol), Pd(OAc)₂ (3 mg, 0.0125 mmol), and DiPheCy₂P (9 mg, 0.025 mmol). The resulting mixture was stirred at 120 °C for 18 h, silica (5 g) was added, volatiles were evaporated, and the product was obtained by flash chromatography.

Butyl 3-(7-Benzylpurine-6-yl)acrylate (5a): Purification of the crude reaction mixture by flash chromatography with ethyl acetate/methanol (20:1) gave the desired product **5a** (45 mg, 54%) as a yellow solid; m.p. 95–97 °C. ¹H NMR (CDCl₃): δ = 0.94 (t, *J* = 7.3 Hz, CH₃, 3 H), 1.38 (m, 2 H, CH₂), 1.66 (m, 2 H, CH₂), 4.19 (t, *J* = 6.4 Hz, 2 H, CH₂O), 5.62 (s, 2 H, CH₂Ph), 7.13 (m, 2 H, ArH), 7.20 (d, *J* = 15 Hz, 1 H, =CH), 7.35 (m, 3 H, ArH), 7.86 (d, *J* = 15 Hz, 1 H, =CH), 8.31 (s, 1 H, 8-H), 9.08 (s, 1 H, 2-H) ppm. ¹³C NMR (CDCl₃): δ = 13.6, 19.1, 30.6, 51.7, 64.9, 123.0, 126.5, 127.7, 129.0, 129.4, 133.8, 135.7, 144.6, 149.8, 153.2, 162.9, 165.8 ppm. IR (CHCl₃): ν̄ = 2962, 2934, 1713, 1582, 1562, 1487, 1453, 1389, 1369, 1336, 1302, 1284, 1158, 970 cm⁻¹. HR MS (EI): calculated for C₁₉H₂₀N₄O₂: 336.1586; found 336.1599.

3-(7-Benzylpurine-6-yl)acrylonitrile (5b): Chromatography with EtOAc/methanol (20:1) gave **5b** (32 mg, 49%) as a yellow solid; m.p. 96–98 °C. ¹H NMR (CDCl₃): δ = 5.63 (s, 2 H, CH₂), 6.85 (d, *J* = 15.5 Hz, 1 H, =CH), 7.09 (m, 2 H, ArH), 7.39 (m, 3 H, ArH), 7.51 (d, *J* = 15.5 Hz, 1 H, =CH), 8.34 (s, 1 H, 8-H), 9.05 (s, 1 H, 8-H) ppm. ¹³C NMR (CDCl₃): δ = 51.6, 116.9, 122.4, 126.2, 129.3, 129.7, 133.5, 141.6, 142.3, 150.5, 153.0, 163.4 ppm. IR (CHCl₃): ν̄ = 2224, 1580, 1562, 1488, 1451, 1391, 1369, 1335, 1165, 952 cm⁻¹. HR MS (EI): calculated for C₁₅H₁₉ClN₄O₂: 261.1014; found 261.1010.

7-Benzyl-6-(3-oxobut-1-enyl)purine (5c): Chromatography with EtOAc/methanol (9:1) gave **5c** (22 mg, 32%) as a yellow solid; m.p. 145–150 °C. ¹H NMR (CDCl₃): δ = 2.3 (s, 3 H, MeCO), 5.65 (s, 2 H, CH₂Ph), 7.14 (d, *J* = 7.7 Hz, 2 H, ArH), 7.37 (m, 3 H, ArH), 7.53 (d, *J* = 15.1 Hz, 1 H, CH=), 7.68 (d, *J* = 15.1 Hz, 1 H, CH=), 8.35 (s, 1 H, 8-H), 9.12 (s, 1 H, 2-H) ppm. ¹³C NMR (CDCl₃): δ = 29.4, 51.7, 123.5, 126.4, 129.0, 129.5, 133.5, 133.6, 133.8, 144.8, 150.0, 153.2, 163.0, 197.1 ppm. IR (CHCl₃): ν̄ = 1695, 1580, 1488, 1455, 1368, 1335 cm⁻¹. HR MS (EI): calculated for C₁₆H₁₄N₄O 278.1168; found 278.1176.

7-Benzyl-6-(2-phenylethenyl)purine (5d):^[29] Chromatography with EtOAc/methanol (9:1) gave **5d** (37 mg, 47%) as a yellow solid; m.p. 179–182 °C. ¹H NMR (CDCl₃): δ = 5.67 (s, 2 H, CH₂Ph), 7.15 (m, 3 H, 2H ArH and 1H CH=), 7.41 (m, 8 H, ArH), 8.23 (d, *J* = 14.6 Hz, 1 H, CH=), 8.32 (s, 1 H, 8-H), 9.09 (s, 1 H, 2-H) ppm. ¹³C NMR (CDCl₃): δ = 51.5, 120.2, 122.2, 125.9, 127.7, 128.7, 128.8, 129.5, 134.9, 135.5, 138.8, 147.7, 149.2, 153.2, 162.2 ppm. IR (CHCl₃): ν̄ = 1631, 1582, 1558, 1487, 1455, 1370 cm⁻¹. HR MS (EI): calculated for C₂₀H₁₆N₄ 312.1375; found 312.1352.

General Procedure for Heck Reactions of 6-Chloro-2-iodopurines 6a and 6b: Dry DMF or acetonitrile (3 mL per 0.25 mmol of iodopurine), then the alkene (4 equiv.) and *i*Pr₂NEt₂ (2 equiv.) were added under argon to a mixture of **6a** or **6b** (1 equiv.) and Pd(dba)₂ (0.05 equiv.). The resulting mixture was stirred for 3 h at the temperature given in Table 2. Silica (5 g) was added, volatiles were evaporated, and a pure product was obtained by flash chromatography.

Butyl 3-(6-Chloro-9-isopropylpurine-2-yl)acrylate (7a): Use of the General Procedure starting from **6a** (81 mg, 0.25 mmol), Pd(dba)₂ (7 mg, 0.0125 mmol), butyl acrylate (128 mg, 1 mmol), and *i*Pr₂NEt (65 mg, 0.5 mmol), with heating at 60 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), gave **7a** (73 mg, 90%) as a yellow solid; m.p. 69–74 °C. ¹H NMR (CDCl₃): δ = 0.98 (t, *J* = 7.4 Hz, 3 H, CH₃), 1.46 (m, 2 H, CH₂), 1.69 (d, *J* = 6.8 Hz, 6 H, CH₃), 1.74 (m, 2 H, CH₂), 4.25 (t, *J* = 6.6 Hz, 2 H, O-CH₂), 4.95 (m, 1 H, CHMe₂), 7.26 (d, *J* = 15.7 Hz, 1 H, =CH), 7.73 (d, *J* = 15.7 Hz, 1 H, =CH), 8.19 (s, 1 H, 8-H) ppm. ¹³C NMR (CDCl₃): δ = 13.7, 19.2, 22.5, 30.7, 48.3, 64.8, 127.4, 131.3, 141.8, 143.8, 150.8, 151.8, 156.5, 166.3 ppm. IR (CHCl₃): ν̄ = 2964, 2937,

2877, 1714, 1652, 1588, 1555, 1487, 1460, 1426, 1392, 1298, 1283, 1250, 1171 cm^{-1} . HR MS (EI): calculated for $\text{C}_{15}\text{H}_{19}\text{ClN}_4\text{O}_2$ 322.1197; found 322.1199.

3-(6-Chloro-9-isopropylpurine-2-yl)acrylonitrile (7b): Use of the General Procedure starting from **6a** (162 mg, 0.5 mmol), $\text{Pd}(\text{dba})_2$ (14 mg, 0.025 mmol), acrylonitrile (106 mg, 2 mmol), and $i\text{Pr}_2\text{NEt}$ (130 mg, 1 mmol), with heating at 120 °C in dry DMF (6 mL) and chromatography with EtOAc/hexane (2:1), afforded **7b** 99 mg (80%) as a yellow solid; m.p. 185–190 °C. ^1H NMR (CDCl_3): δ = 1.69 (d, J = 6.8 Hz, 6 H, CH_3), 4.94 (m, 1 H, CHMe_2), 6.85 (d, J = 16.1 Hz, 1 H, =CH), 7.51 (d, J = 16.2 Hz, 1 H, =CH), 8.23 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 22.5, 48.4, 105.6, 117.1, 131.8, 144.3, 147.8, 151.1, 151.7, 154.7 ppm. IR (CHCl_3): $\tilde{\nu}$ = 2226, 1586, 1553, 1485, 1461, 1390, 1340, 1322, 1173, 1147, 967, 917 cm^{-1} . HR MS (EI): calculated for $\text{C}_{11}\text{H}_{10}\text{ClN}_5$ 247.0625; found 247.0628.

6-Chloro-9-isopropyl-2-(2-phenylethenyl)purine (7c): Use of the General Procedure starting from **6a** (81 mg, 0.25 mmol), $\text{Pd}(\text{dba})_2$ (7 mg, 0.0125 mmol), styrene (104 mg, 1 mmol), and $i\text{Pr}_2\text{NEt}$ (65 mg, 0.5 mmol), with heating at 80 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), gave **7c** (65 mg, 87%) as a yellow solid; m.p. 147–149 °C. ^1H NMR (CDCl_3): δ = 1.69 (d, J = 6.8 Hz, 6 H, CH_3), 4.98 (m, 1 H, CHMe_2), 7.29 (d, J = 15.7 Hz, 1 H, =CH), 7.35 (m, 1 H, ArH), 7.41 (m, 2 H, ArH), 7.65 (d, J = 7.4 Hz, 2 H, ArH), 8.04 (d, J = 15.9 Hz, 1 H, =CH), 8.13 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 22.6, 47.8, 126.6, 127.6, 128.8, 129.1, 130.1, 136.0, 138.2, 142.7, 150.5, 152.0, 159.1 ppm. IR (CHCl_3): $\tilde{\nu}$ = 2931, 2857, 1639, 1591, 1551, 1495, 1454, 1425, 1388, 1344, 1323, 1281 cm^{-1} . HR MS (EI): calculated for $\text{C}_{16}\text{H}_{15}\text{ClN}_4$ 298.0985; found: 298.0981.

6-Chloro-9-isopropyl-2-(3-oxobut-1-enyl)purine (7d): Use of the General Procedure starting from **6a** (81 mg, 0.25 mmol), $\text{Pd}(\text{dba})_2$ (7 mg, 0.0125 mmol), methyl vinyl ketone (70 mg, 1 mmol), and $i\text{Pr}_2\text{NEt}$ (65 mg, 0.5 mmol), with stirring at 80 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), afforded **7d** (64 mg, 97%) as a yellow solid; m.p. 183–187 °C. ^1H NMR (CDCl_3): δ = 1.69 (d, J = 6.8 Hz, 6 H, CH_3), 2.46 (s, 3 H, COCH_3), 4.95 (m, 1 H, CHMe_2), 7.44 (d, J = 16.0 Hz, 1 H, =CH), 7.57 (d, J = 16.0 Hz, 1 H, =CH), 8.21 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 22.5, 27.8, 48.4, 131.4, 134.8, 140.6, 144.0, 150.8, 151.9, 156.7, 198.5 ppm. IR (CHCl_3): $\tilde{\nu}$ = 3051, 1677, 1628, 1588, 1554, 1424, 1389, 1266 cm^{-1} . HR MS (EI): calculated for $\text{C}_{12}\text{H}_{13}\text{ClN}_4\text{O}$ 264.0778; found 264.0772.

Butyl [6-Chloro-9-(*O*-triacetyl- β -D-ribofuranosyl)purine-2-yl]acrylate (7e): Use of the General Procedure starting from **6b** (180 mg, 0.25 mmol), $\text{Pd}(\text{dba})_2$ (7 mg, 0.0125 mmol), acrylonitrile (128 mg, 1 mmol), and $i\text{Pr}_2\text{NEt}$ (65 mg, 0.5 mmol), with heating at 80 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), gave **7e** (127 mg, 94%) as a white foam. ^1H NMR (CDCl_3): δ = 0.98 (t, J = 7.4 Hz, 3 H, CH_3), 1.46 (m, 2 H, CH_2), 1.70 (m, 2 H, CH_2), 2.10 (s, 6 H, COCH_3), 2.19 (s, 3 H, COCH_3), 4.25 (t, J = 6.6 Hz, 2 H, O- CH_2), 4.38 (dd, J_1 = 4.1, J_2 = 12.4 Hz, 1 H, CH_2O), 4.45 (dd, J_1 = 2.9, J_2 = 12.3 Hz, 1 H, CH_2OAc), 4.5 (m, 1 H, CH), 5.68 (t, J = 5.2 Hz, 1 H, AcO-CH), 5.92 (t, J = 5.2 Hz, 1 H, AcO-CH), 6.24 (d, J = 4.9 Hz, 1 H, O-CH), 7.27 (d, J = 15.7 Hz, 1 H, =CH), 7.72 (d, J = 15.7 Hz, 1 H, =CH), 8.31 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 13.7, 19.2, 20.4, 20.5, 20.7, 30.7, 62.8, 64.9, 70.3, 73.3, 80.4, 86.7, 128.3, 131.5, 141.2, 144.1, 151.5, 151.6, 157.4, 166.1, 169.3, 169.5, 170.2 ppm. IR (CHCl_3): $\tilde{\nu}$ = 2964, 2937, 1753, 1715, 1591, 1557, 1390, 1298, 1284, 1171 cm^{-1} . HR MS (EI): calculated for $\text{C}_{23}\text{H}_{27}\text{ClN}_4\text{O}_9$ 538.1467; found 538.1489.

6-Chloro-2-(2-phenylethenyl)-9-(*O*-triacetyl- β -D-ribofuranosyl)purine (7f): Use of the General Procedure starting from **6b** (159 mg, 0.30 mmol), $\text{Pd}(\text{dba})_2$ (6 mg, 0.011 mmol), styrene (125 mg, 1.2 mmol), and $i\text{Pr}_2\text{NEt}$ (78 mg, 0.6 mmol), with heating at 80 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), gave **7f** (120 mg, 78%) as a white foam. ^1H NMR (CDCl_3): δ = 2.05 (s, 3 H, COCH_3), 2.14 (s, 3 H, COCH_3), 2.20 (s, 3 H, COCH_3), 4.37 (dd, J_1 = 5.1, J_2 = 13.1 Hz, 1 H, CH_2OAc), 4.49 (m, 2 H, 1H CH and 1H CH_2OAc), 5.89 (t, J = 5.5 Hz, 1 H, AcO-CH), 6.09 (t, J = 4.6 Hz, 1 H, AcO-CH), 6.20 (d, J = 4.4 Hz, 1 H, O-CH), 7.30 (d, J = 16.0 Hz, 1 H, =CH), 7.37 (m, 1 H, ArH), 7.42 (m, 2 H, ArH), 7.69 (d, J = 7.3 Hz, 2 H, ArH), 8.10 (d, J = 16.0 Hz, 1 H, =CH), 8.20 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 20.4, 20.6, 20.7, 62.6, 70.1, 73.2, 80.1, 87.2, 126.0, 127.8, 128.8, 129.3, 130.4, 135.8, 139.3, 143.5, 151.2, 151.7, 160.1, 69.4, 169.5, 170.3 ppm. IR (CHCl_3): $\tilde{\nu}$ = 3051, 1752, 1594, 1554, 1498, 1452, 1390, 1266 cm^{-1} . HR MS (EI): calculated for $\text{C}_{24}\text{H}_{23}\text{ClN}_4\text{O}_7$ 514.1255; found 514.1277.

6-Chloro-2-(3-oxobut-2-enyl)-9-(*O*-triacetyl- β -D-ribofuranosyl)purine (7g): Use of the General Procedure starting from **6b** (159 mg, 0.30 mmol), $\text{Pd}(\text{dba})_2$ (9 mg, 0.015 mmol), methyl vinyl ketone (84 mg, 1.2 mmol), and $i\text{Pr}_2\text{NEt}$ (78 mg, 0.6 mmol), with heating at 80 °C in dry acetonitrile (3 mL) and chromatography with EtOAc/hexane (2:1), afforded **7g** (119 mg, 82%) as a white foam. ^1H NMR (CDCl_3): δ = 2.09 (s, 3 H, COCH_3), 2.11 (s, 3 H, COCH_3), 2.19 (s, 3 H, COCH_3), 2.47 (s, 3 H, COCH_3), 4.36–4.52 (m, 3 H, 2H CH_2OAc and 1H CH), 5.73 (t, J = 5.5 Hz, 1 H, AcO-CH), 6.09 (t, J = 5.1 Hz, 1 H, AcO-CH), 6.23 (d, J = 4.5 Hz, 1 H, O-CH), 7.49 (d, J = 16.0 Hz, 1 H, =CH), 7.57 (d, J = 16.0 Hz, 1 H, =CH), 8.32 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 20.4, 20.5, 20.7, 28.0, 62.8, 70.3, 73.2, 80.3, 86.9, 131.6, 135.4, 139.8, 144.4, 151.5, 151.6, 157.6, 169.3, 169.5, 170.2, 198.4 ppm. IR (CHCl_3): $\tilde{\nu}$ = 1753, 1678, 1557, 1390, 1368, 1266, 1226 cm^{-1} . HR MS (EI): calculated for $\text{C}_{20}\text{H}_{21}\text{ClN}_4\text{O}_8$ 480.1048; found 480.1057.

Methyl 3-(6-Chloro-9-isopropylpurine-2-yl)methacrylate (7h): Dry DMF (3 mL), then methyl methacrylate (100 mg, 1 mmol) and $i\text{Pr}_2\text{NEt}$ (65 mg, 0.5 mmol) were added under argon to a mixture of **6a** (81 mg, 0.25 mmol), $\text{Pd}(\text{dba})_2$ (7 mg, 0.0125 mmol) and Di- PhCeY_2P (9 mg, 0.025 mmol). The resulting mixture was stirred at 120 °C for 3 d. Purification by flash chromatography with EtOAc/hexane (2:1) gave **9** (38 mg, 54%) as a bright yellow oil. ^1H NMR (CDCl_3): δ = 1.69 (d, J = 6.8 Hz, 6 H, CH_3), 2.53 (s, 3 H, CH_3), 3.85 (s, 3 H, OCH_3), 4.91 (m, 1 H, CHMe_2), 7.74 (s, 1 H, =CH), 8.19 (s, 1 H, 8-H) ppm. ^{13}C NMR (CDCl_3): δ = 14.5, 22.4, 48.4, 52.3, 130.2, 135.2, 136.5, 143.8, 150.2, 151.5, 157.8, 168.8 ppm. IR (CHCl_3): $\tilde{\nu}$ = 2955, 2856, 1714, 1590, 1554, 1489, 1460, 1438, 1393, 1378, 1345, 1277, 1172, 1145, 1122 cm^{-1} . HR MS (EI): calculated for $\text{C}_{13}\text{H}_{15}\text{ClN}_4\text{O}_2$ 294.0884; found 294.0888.

Supporting Information (see also the footnote on the first page of this article): ^1H and ^{13}C NMR spectra of compounds **3**, **5a–d**, and **7a–h**.

Acknowledgments

This project was supported by the Research Centre “The Structure and Synthetic Applications of Transition Metal Complexes – LC06070” of the Ministry of Education, Youth and Sports of the Czech Republic, by the MSM6046137301 research project of the same Ministry, and by the Grant Agency of the Czech Republic (grant No. 203/06/0888).

- [1] For review on biological activities displayed by purines see: M. Legraverend, D. S. Grierson, *Bioorg. Med. Chem.* **2006**, *14*, 3987–4006.
- [2] A. K. Bakkestuen, L.-L. Gundersen, G. Langli, F. Liu, J. M. J. Nolsøe, *Bioorg. Med. Chem. Lett.* **2000**, *10*, 1207–1210.
- [3] A. Bråthe, L.-L. Gundersen, J. Nissen-Meyer, F. Rise, B. Spilsberg, *Bioorg. Med. Chem. Lett.* **2003**, *13*, 877–880.
- [4] a) A. Bråthe, L.-L. Gundersen, F. Rise, A. B. Eriksen, A. V. Vollsnes, L. Wang, *Tetrahedron* **1999**, *55*, 211–228; b) A. Bråthe, L.-L. Gundersen, F. Rise, A. B. Eriksen, *J. Plant Growth Regul.* **2005**, *24*, 41–45.
- [5] A. Bråthe, G. Andresen, L.-L. Gundersen, K. E. Malterud, F. Rise, *Bioorg. Med. Chem.* **2002**, *10*, 1581–1586.
- [6] a) M. Hocek, I. Votruba, *Bioorg. Med. Chem. Lett.* **2002**, *12*, 1055–1058; b) M. Hocek, H. Dvořáková, I. Císařová, *Collect. Czech. Chem. Commun.* **2002**, *67*, 1560–1578.
- [7] F. Nagatsugi, K. Uemura, S. Nakashima, M. Maeda, S. Sasaki, *Tetrahedron* **1997**, *53*, 3035–3044.
- [8] W. M. Odijk, G. J. Koomen, *Tetrahedron* **1985**, *41*, 1893–1904.
- [9] S. Vittori, E. Camaioni, E. Di Francesco, R. Volpini, A. Monopoli, S. Dionisotti, E. Ongini, G. Cristalli, *J. Med. Chem.* **1996**, *39*, 4211–4217.
- [10] A. Hampton, *J. Heterocycl. Chem.* **1974**, *11*, 255–256.
- [11] E. C. Taylor, S. F. Martin, *J. Am. Chem. Soc.* **1974**, *96*, 8095–8102.
- [12] T. Ch. Berg, L.-L. Gundersen, A. B. Eriksen, K. E. Malterud, *Eur. J. Org. Chem.* **2005**, 4988–4994.
- [13] M. Kuchař, R. Pohl, I. Votruba, M. Hocek, *Eur. J. Org. Chem.* **2006**, 5083–5098.
- [14] A. Matsuda, M. Shinozaki, Y. Toyofumi, H. Homma, R. Nomoto, T. Miyasaka, Y. Watanabe, T. Abiru, *J. Med. Chem.* **1992**, *35*, 241–252.
- [15] G. Sági, L. Ötvös, S. Ikeda, G. Andrei, R. Snoeck, E. De Clercq, *J. Med. Chem.* **1994**, *37*, 1307–1311.
- [16] For a recent review see: M. Hocek, *Eur. J. Org. Chem.* **2003**, 245–254.
- [17] See for instance: a) A. A. Van Aerschot, P. Mamos, N. J. Weyns, S. Ikeda, E. De Clercq, P. A. Herdewijn, *J. Med. Chem.* **1993**, *36*, 2938–2942; b) L.-L. Gundersen, *Tetrahedron Lett.* **1994**, *35*, 3155–3158; c) L.-L. Gundersen, A. K. Bakkestuen, A. J. Aasen, H. Øveras, F. Rise, *Tetrahedron* **1994**, *50*, 9743–9756; d) F. Nagatsugi, K. Uemura, S. Nakashima, M. Maeda, S. Sasaki, *Tetrahedron Lett.* **1995**, *36*, 421–424.
- [18] a) M. Havelková, M. Hocek, M. Česnek, D. Dvořák, *Synlett* **1999**, 1145–1147; b) M. Havelková, D. Dvořák, M. Hocek, *Synthesis* **2001**, 1704–1710; c) F. Berrée, P. G.-L. Bleis, B. Carboni, *Tetrahedron Lett.* **2002**, *43*, 4935–4938.
- [19] a) K. Kato, H. Hayakawa, H. Tanaka, H. Kumamoto, S. Shindoh, S. Shuto, T. Miyasaka, *J. Org. Chem.* **1997**, *62*, 6833–6841; b) K. Kato, H. Hayakawa, H. Tanaka, H. Kumamoto, T. Miyasaka, *Tetrahedron Lett.* **1995**, *36*, 6507–6510.
- [20] K. A. Jacobson, D. Shi, C. Gallo-Rodriguez, M. Manning, C. Müller, J. W. Daly, J. L. Meumayer, L. Kiriasis, W. Pfleiderer, *J. Med. Chem.* **1993**, *36*, 2639–2644.
- [21] M. Havelková, M. Studenovský, D. Dvořák, *Collect. Czech. Chem. Commun.* **2000**, *65*, 797–804.
- [22] T. Tobrman, D. Dvořák, *Tetrahedron Lett.* **2004**, *45*, 273–276.
- [23] T. Tobrman, D. Dvořák, *Collect. Czech. Chem. Commun.* **2007**, *72*, 1365–1374.
- [24] A study to determine whether the higher yield of the Heck product in the case of 7-benzyl-6-iodopurine is a result of the steric hindrance of the benzyl group or due to the different electronic distribution in 7-benzyl-6-iodopurine is now being undertaken in our laboratory.
- [25] Interestingly, only traces of the corresponding Heck product were detected if the used reaction conditions were applied in the reactions between 6-chloro-8-iodo-9-isopropylpurine and butyl acrylate or styrene. Optimization of the reaction conditions to achieve Heck reactions of 8-halopurines will thus require further study.
- [26] T. C. McKenzie, J. W. Epstein, *J. Org. Chem.* **1982**, *47*, 4881–4884.
- [27] M. Legraverend, O. Ludwig, E. Bisagni, S. Leclerc, L. Meijer, N. Giocanti, R. Sadri, V. Favaudon, *Bioorg. Med. Chem.* **1999**, *7*, 1281–1293.
- [28] V. Nair, S. G. Richardson, *Synthesis* **1982**, 670–672.
- [29] Compound **5d** was reported in connection with its biological activity (A. Bråthe, L.-L. Gundersen, K. E. Malterud, F. Rise, *Arch. Pharm. Chem. Life Sci.* **2005**, *338*, 159–166) with a ref.^[2] to its preparation. However, ref.^[2] does not mention compound **5d**.

Received: January 25, 2008
Published Online: April 30, 2008